NASDAQ · HYPMY
Healthcare · Drug Manufacturers - Specialty & Generic
$5.33
Up+$0.03 (+0.57%)
Updated Oct 13, 2026, 12:26 PM
SID Score
5.8/10
Composite research score
Smart Money
46/100
Neutral
Price performance · HYPMY
1M range · 0 trading sessions · Daily adjusted prices
HYPMY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HYPMY.
Company
Market Activity
Research & News
HYPMY research
Company profile and research snapshot.
HYPERA SA S/ADR
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 21, 2026
Hypera (OTC:HYPMY) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
SeekingAlpha · Aug 11, 2026
Hypera S.A. (HYPMY) Q2 2026 Earnings Call August 7, 2026 10:00 AM EDTCompany ParticipantsBreno Pires de Oliveira - Chief Executive OfficerRamon Frutuoso...
SeekingAlpha · Aug 7, 2026
2026-08-07. The following slide deck was published by Hypera S.A.
Benzinga · Aug 6, 2026
Hypera (OTC:HYPMY) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a 0 percent decrease over earnings of $0.14 per share from the same period last year. The company
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HYPMY.
